Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
暂无分享,去创建一个
[1] B T Hyman,et al. Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels , 1998, Journal of neuropathology and experimental neurology.
[2] Holtzman,et al. Clearance of amyloid beta-peptide from brain: transport or metabolism? , 2000, Nature medicine.
[3] R. Tanzi,et al. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.
[4] J. Ringman,et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. , 2005, Journal of Alzheimer's disease : JAD.
[5] C. Pieper,et al. The distribution of cerebrovascular amyloid in Alzheimer’s disease varies with ApoE genotype , 2006, Acta Neuropathologica.
[6] Da-Zhi Wang,et al. The serum response factor coactivator myocardin is required for vascular smooth muscle development , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] O. Ottersen,et al. Immunocytochemical evidence that amyloid β (1–42) impairs endogenous antioxidant systems in vivo , 2003, Neuroscience.
[8] K. Jellinger,et al. Alzheimer disease and cerebrovascular pathology: an update , 2002, Journal of Neural Transmission.
[9] Jeffrey F. Thompson,et al. Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] M. Rafii,et al. Agrin and microvascular damage in Alzheimer's disease , 2000, Neurobiology of Aging.
[11] T. Saido,et al. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. , 2006, Neuroscience research.
[12] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[13] J. C. Torre. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.
[14] Katie Hamm,et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.
[15] R. Deane,et al. Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .
[16] Dietmar Rudolf Thal,et al. Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease , 2008, Acta Neuropathologica.
[17] R. Mayeux,et al. Atherosclerosis and AD , 2005, Neurology.
[18] T. Grabowski,et al. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy , 2001, Annals of neurology.
[19] A. Goate,et al. Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.
[20] C. Iadecola,et al. Aβ-Induced Vascular Oxidative Stress and Attenuation of Functional Hyperemia in Mouse Somatosensory Cortex , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] T. Miyatake,et al. Cerebral amyloid angiopathy: A significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly , 1993, Journal of the Neurological Sciences.
[22] R. Carare,et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease , 2008, Acta Neuropathologica.
[23] D. Attwell,et al. Bidirectional control of CNS capillary diameter by pericytes , 2006, Nature.
[24] 美晴 佐村木,et al. Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease , 2007 .
[25] B. Puig,et al. Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer's disease and cerebral amyloid angiopathy. , 2007, Neuroscience.
[26] C. Iadecola,et al. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. , 2006, Journal of applied physiology.
[27] Da-Zhi Wang,et al. Activation of Cardiac Gene Expression by Myocardin, a Transcriptional Cofactor for Serum Response Factor , 2001, Cell.
[28] D. D'urso,et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[29] Jeffrey W. Streb,et al. Myocardin: a component of a molecular switch for smooth muscle differentiation. , 2002, Journal of molecular and cellular cardiology.
[30] B. Hyman,et al. The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate* , 2005, Journal of Biological Chemistry.
[31] S. D. Preston,et al. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.
[32] J. Wegiel,et al. The complex of microglial cells and amyloid star in three-dimensional reconstruction , 2004, Acta Neuropathologica.
[33] José A Fernández,et al. Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage , 2006, Nature Medicine.
[34] Cornelis J. Stam,et al. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease , 2005, NeuroImage.
[35] D. Holtzman,et al. Clearance of amyloid β-peptide from brain: transport or metabolism? , 2000, Nature Medicine.
[36] A. Scheibel,et al. Alzheimer's disease as a capillary dementia. , 1989, Annals of medicine.
[37] José A Fernández,et al. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. , 2002, Seminars in hematology.
[38] L. Badimón,et al. Sterol regulatory element-binding protein-2 negatively regulates low density lipoprotein receptor-related protein transcription. , 2006, Journal of molecular biology.
[39] T. Hattori,et al. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. , 2001, Clinical neuropathology.
[40] M. D'Andrea,et al. Aβ peptides can enter the brain through a defective blood–brain barrier and bind selectively to neurons , 2007, Brain Research.
[41] A. Hofman,et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.
[42] J. Koziol,et al. Focal Cerebral Ischemia Induces Active Proteases That Degrade Microvascular Matrix , 2004, Stroke.
[43] S. Hickman,et al. Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice , 2008, The Journal of Neuroscience.
[44] P. Luiten,et al. Cerebral microvascular pathology in aging and Alzheimer's disease , 2001, Progress in Neurobiology.
[45] G. Rosenberg. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases , 2009, The Lancet Neurology.
[46] A. M. Saunders,et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.
[47] T. Saido,et al. Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease Towards presymptomatic diagnosis, prevention and therapy , 2006, Neuroscience Research.
[48] R. Deane,et al. Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor* , 2004, Journal of Biological Chemistry.
[49] D. Connor,et al. Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles , 2006, Acta Neuropathologica.
[50] B. Zlokovic,et al. Substitution at codon 22 reduces clearance of Alzheimer’s amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood , 2002, Neurobiology of Aging.
[51] R O Weller,et al. Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. , 1990, Journal of anatomy.
[52] C. Betsholtz,et al. Pericytes and vascular stability. , 2006, Experimental cell research.
[53] B. Zlokovic. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.
[54] J. McLaurin,et al. Selective targeting of perivascular macrophages for clearance of β-amyloid in cerebral amyloid angiopathy , 2009, Proceedings of the National Academy of Sciences.
[55] D. Holtzman,et al. Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[56] Eric E. Smith,et al. Amyloid Angiopathy–Related Vascular Cognitive Impairment , 2004, Stroke.
[57] B. Zlokovic,et al. The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.
[58] N. Schuff,et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. , 2005, Radiology.
[59] A. Hofman,et al. Atherosclerosis and risk for dementia , 2007, Annals of neurology.
[60] P. Wesseling,et al. Amyloid‐β‐induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype , 2000, Annals of the New York Academy of Sciences.
[61] Andrew Brooks,et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype , 2007, Proceedings of the National Academy of Sciences.
[62] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[63] K. Jellinger,et al. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology , 2007, Journal of the Neurological Sciences.
[64] P. Hof,et al. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease , 2004, Neurological research.
[65] G. Perry,et al. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease , 1993, Brain Research.
[66] R. Deane,et al. SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells , 2009, Nature Cell Biology.
[67] B. Zlokovic. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. , 1996, Life Science.
[68] Hugh Davson,et al. Physiology and Pathophysiology of the Cerebrospinal Fluid , 1987 .
[69] M. Tapner,et al. Soluble Low Density Lipoprotein Receptor-related Protein (LRP) Circulates in Human Plasma* , 1997, The Journal of Biological Chemistry.
[70] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[71] R. Tanzi,et al. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.
[72] K. Jellinger,et al. Alzheimer’s disease pathology influences severity and topographical distribution of cerebral amyloid angiopathy , 2005, Acta Neuropathologica.
[73] C. Stoeckert,et al. Defining the mammalian CArGome. , 2005, Genome research.
[74] A. Hofman,et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β–amyloid precursor protein gene , 1992, Nature Genetics.
[75] P. Hedera,et al. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. , 1995, Neuroreport.
[76] J. Hardy,et al. Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). , 1990, Science.
[77] A. Goate,et al. Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.
[78] M. D. de Leon,et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[79] R. Kalaria,et al. Increased collagen content of cerebral microvessels in Alzheimer's disease , 1995, Brain Research.
[80] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[81] B. Zlokovic,et al. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. , 2000, American journal of physiology. Cell physiology.
[82] S. Younkin,et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.
[83] B. Puig,et al. RETRACTED: Oxidative damage of 14-3-3 zeta and gamma isoforms in Alzheimer’s disease and cerebral amyloid angiopathy , 2007, Neuroscience.
[84] R. Deane,et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. , 2004, Neuron.
[85] Gregory M. Szilagyi,et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. , 2008, Archives of neurology.
[86] Berislav V. Zlokovic,et al. Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.
[87] P. Wesseling,et al. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. , 1999, The American journal of pathology.
[88] D. Begley,et al. Structural and functional aspects of the blood-brain barrier. , 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[89] E. Matsubara,et al. Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β , 1997, Journal of neurochemistry.
[90] T. Beach,et al. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease , 2004, Neurological research.
[91] T. Iwatsubo,et al. Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid β-Peptide by the Liver , 2006, Pharmaceutical Research.
[92] J. Parks,et al. Neurotoxic Aβ peptides increase oxidative stress in vivo through NMDA‐receptor and nitric‐oxide‐synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro , 2001, Journal of neurochemistry.
[93] R. Koehler,et al. Dopamine Receptor Modulation of Hypoxic—Ischemic Neuronal Injury in Striatum of Newborn Piglets , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[94] Thomas Wisniewski,et al. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.
[95] Peter J. Lenting,et al. LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.
[96] E. Zhang,et al. Perivascular cells act as scavengers in the cerebral perivascular spaces and remain distinct from pericytes, microglia and macrophages , 2004, Acta Neuropathologica.
[97] Don L. Armstrong,et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease , 2005, Nature Medicine.
[98] R. Deane,et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration , 2008, Nature Neuroscience.
[99] C. Iadecola. Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[100] A. Drzezga,et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[101] W. V. Van Nostrand,et al. Pathogenic Aβ induces the expression and activation of matrix metalloproteinase‐2 in human cerebrovascular smooth muscle cells , 2003 .
[102] K. Welsh-Bohmer,et al. Vascular Smooth Muscle Actin Is Reduced in Alzheimer Disease Brain: A Quantitative Analysis , 2004, Journal of neuropathology and experimental neurology.
[103] Hiroshi Matsuda,et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT , 2005, NeuroImage.
[104] A. Hofman,et al. Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study , 2005, Annals of neurology.
[105] Uwe Haberkorn,et al. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease , 2007, Psychiatry Research: Neuroimaging.
[106] C. Geula,et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.
[107] H. Vinters,et al. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. , 1994, Ultrastructural Pathology.
[108] P. Reynolds,et al. Midkine Is Regulated by Hypoxia and Causes Pulmonary Vascular Remodeling* , 2004, Journal of Biological Chemistry.
[109] B. Zlokovic,et al. Kinetics and Na independence of amino acid uptake by blood side of perfused sheep choroid plexus. , 1990, The American journal of physiology.